Cao Menghan, Pan Di, Li Yuqi, Pei Zicheng, Wang Runbang, Zhang Bo, Bian Chaorong, Gu Qinghao, Qu Pengfei, Yu Chenchen, Liu Haonan, Han Zhengxiang
Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Department of Oncology, Nanjing Medical University, Nanjing, China.
Eur J Med Res. 2025 Aug 23;30(1):793. doi: 10.1186/s40001-025-03072-7.
To assess the prognostic relevance of androgen receptor (AR) expression in patients following modified radical surgery for invasive breast cancer.
A cohort of 515 patients who underwent modified radical mastectomy for breast cancer from July 2016 to November 2017 was analyzed. Immunohistochemistry was employed to determine the expression levels of AR, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER-2), cell proliferation nuclear antigen (Ki-67), oncogene (P-53), cytokeratin 5/6 (CK5/6), topoisomerase-2 (TOPO-2), and epidermal growth factor receptor (EGFR). The correlation between AR expression and clinicopathological features as well as prognosis was examined. Multifactorial analysis using Cox proportional risk regression identified independent prognostic factors for disease-free survival (DFS), and a nomogram model was developed based on these factors.
Patients in the AR-positive group demonstrated a significantly higher frequency of low histologic grade (grade 1-2), ER positive, PR positive, TOPO-2-negative, CK5/6-negative, and EGFR-negative as compared to the AR-negative group (P < 0.05). Among ER( +)/HER-2(-) and ER( +)/HER-2( +) patients with breast cancer, AR-positive individuals exhibited prolonged DFS (P < 0.05). Conversely, in ER(-)/HER-2( +) and ER(-)/HER-2(-) patients with breast cancer, AR expression did not significantly influence disease-free survival (P > 0.05). Multifactorial regression analysis identified AR/ER ratio, histological classification, and lymph node metastasis as independent prognostic factors for DFS (all P < 0.05). The developed nomogram model underscored the significance of histological classification as the primary predictive factor for patient outcomes, followed by AR/ER ratio and lymph node metastasis CONCLUSION: AR expression holds varying prognostic implications across different breast cancer subtypes, with AR positivity indicating a favorable prognosis, particularly in ER-positive tumors.
评估雄激素受体（AR）表达对浸润性乳腺癌改良根治术后患者预后的相关性。
分析2016年7月至2017年11月期间接受乳腺癌改良根治术的515例患者队列。采用免疫组织化学法测定AR、雌激素受体（ER）、孕激素受体（PR）、人表皮生长因子受体2（HER-2）、细胞增殖核抗原（Ki-67）、癌基因（P-53）、细胞角蛋白5/6（CK5/6）、拓扑异构酶-2（TOPO-2）和表皮生长因子受体（EGFR）的表达水平。检测AR表达与临床病理特征及预后之间的相关性。使用Cox比例风险回归进行多因素分析，确定无病生存期（DFS）的独立预后因素，并基于这些因素建立列线图模型。
与AR阴性组相比，AR阳性组患者低组织学分级（1-2级）、ER阳性、PR阳性、TOPO-2阴性、CK5/6阴性和EGFR阴性的频率显著更高（P<0.05）。在ER(+)/HER-2(-)和ER(+)/HER-2(+)乳腺癌患者中，AR阳性个体的DFS延长（P<0.05）。相反，在ER(-)/HER-2(+)和ER(-)/HER-2(-)乳腺癌患者中，AR表达对无病生存期无显著影响（P>0.05）。多因素回归分析确定AR/ER比值、组织学分类和淋巴结转移为DFS的独立预后因素（均P<0.05）。所建立的列线图模型强调组织学分类作为患者预后主要预测因素的重要性，其次是AR/ER比值和淋巴结转移。结论：AR表达在不同乳腺癌亚型中具有不同的预后意义，AR阳性表明预后良好，尤其是在ER阳性肿瘤中。
